Infecting tumors: the war on cancer goes viral
Cancer Oncolytic viruses Immunotherapy

Infecting tumors: the war on cancer goes viral

Dr. Jamie A.G. Hamilton
Dr. Jamie A.G. Hamilton

In 10 seconds? Scientists are making advancements in increasing the potential of an emerging anti-cancer therapy, the use of 'oncolytic viruses'. A 2021 review paper details how the potential of such viruses can be increased to attack tumors.

What’s happening? According to the World Health Organization, cancer was responsible for nearly 10 million deaths in 2020. While our understanding of what happens with cancer on the cellular level has improved, effective treatments that can specifically target cancer cells continue to lag behind. Scientists have been turning to humanity's ancient foe, the virus, to develop a novel treatment for cancer with less side effects. So-called ‘oncolytic viruses’ are being engineered to improve their cancer-targeting potential.

Get unlimited access to our 3-min Digests and other premium features!

Choose your plan.

Sparrow Insiders

$0 (Limited Offer)
  • Receive our daily Digest in your inbox
  • Created & reviewed by real scientists
  • Preview 380+ Digests in our library
  • Upgrade for unlimited learning
  • Unsubscribe anytime
  • Subject to availability
Join our first 25k subscribers for free! Signup Progress Bar Subscribe now for free

Sparrow Unlimited

$19 / month
  • Talk with our scientists and ask them anything
  • Access 380+ summaries anywhere, anytime
  • Listen to our premium podcast
  • Weekly newsletter of the top 5 scientific findings
  • Daily updates with new content
  • Support independent science publishing
  • No advertisement
  • Cancel anytime
Learn more Subscribe now

Sparrow Unlimited

$99 / year
  • One easy payment - save 56%
  • Talk with our scientists and ask them anything
  • Access 380+ summaries anywhere, anytime
  • Listen to our premium podcast
  • Weekly newsletter of the top 5 scientific findings
  • Daily updates with new content
  • Support independent science publishing
  • No advertisement
  • Cancel anytime
Learn more Subscribe now